Do analysts prefer RNAZ or GNLX?

Genelux has a consensus price target of $18.00, indicating a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is RNAZ or GNLX more profitable?

Genelux's return on equity of -205.85% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Genelux N/A -205.85% -138.79%

Does the media favor RNAZ or GNLX?

In the previous week, Genelux had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for TransCode Therapeutics. Genelux's average media sentiment score of 0.51 beat TransCode Therapeutics' score of 0.44 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RANI or RNAZ?

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 995.12%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rani Therapeutics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RANI or RNAZ more profitable?

Rani Therapeutics' return on equity of -104.60% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% TransCode Therapeutics N/A -875.35% -37.46%

Does the media refer more to RANI or RNAZ?

In the previous week, Rani Therapeutics had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 2 mentions for TransCode Therapeutics. Rani Therapeutics' average media sentiment score of 0.53 beat TransCode Therapeutics' score of 0.44 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer IMDX or RNAZ?

Oncocyte currently has a consensus target price of $10.50, indicating a potential upside of 211.57%. Given Oncocyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncocyte is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncocyte 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor IMDX or RNAZ?

In the previous week, Oncocyte and Oncocyte both had 2 articles in the media. TransCode Therapeutics' average media sentiment score of 0.44 beat Oncocyte's score of -0.63 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BDTX or RNAZ more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% TransCode Therapeutics N/A -875.35% -37.46%

Does the media refer more to BDTX or RNAZ?

In the previous week, Black Diamond Therapeutics had 4 more articles in the media than TransCode Therapeutics. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 2 mentions for TransCode Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.92 beat TransCode Therapeutics' score of 0.44 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OKUR or RNAZ?

OnKure Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 626.14%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe OnKure Therapeutics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, OKUR or RNAZ?

OnKure Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A

Is OKUR or RNAZ more profitable?

OnKure Therapeutics' return on equity of -49.01% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% TransCode Therapeutics N/A -875.35% -37.46%

TransCode Therapeutics (RNAZ) Competitors

$1.86 +0.15 (+8.77%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.84 -0.02 (-1.29%)

As of 10/9/2026 07:30 PM Eastern

Compare

RNAZ vs. GNLX, RANI, IMDX, BDTX, and OKUR

Should you buy TransCode Therapeutics stock or one of its competitors? TransCode Therapeutics's main competitors and comparable companies include Genelux (GNLX), Rani Therapeutics (RANI), Oncocyte (IMDX), Black Diamond Therapeutics (BDTX), and OnKure Therapeutics (OKUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TransCode Therapeutics compare to Genelux?

TransCode Therapeutics (NASDAQ:RNAZ) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Genelux had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for TransCode Therapeutics. Genelux's average media sentiment score of 0.51 beat TransCode Therapeutics' score of 0.44 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransCode Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Genelux has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

37.3% of Genelux shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genelux has higher revenue and earnings than TransCode Therapeutics. Genelux is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Genelux	$8K	14,478.40	-$32.15M	-$0.86	N/A

Genelux has a consensus price target of $18.00, indicating a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Genelux's return on equity of -205.85% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Genelux	N/A	-205.85%	-138.79%

Summary

Genelux beats TransCode Therapeutics on 12 of the 15 factors compared between the two stocks.

How does TransCode Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Rani Therapeutics' return on equity of -104.60% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
TransCode Therapeutics	N/A	-875.35%	-37.46%

Rani Therapeutics has higher revenue and earnings than TransCode Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$4.88M	22.84	-$29.67M	-$0.27	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Rani Therapeutics had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 2 mentions for TransCode Therapeutics. Rani Therapeutics' average media sentiment score of 0.53 beat TransCode Therapeutics' score of 0.44 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 995.12%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rani Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rani Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Summary

Rani Therapeutics beats TransCode Therapeutics on 12 of the 15 factors compared between the two stocks.

How does TransCode Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

TransCode Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
TransCode Therapeutics	N/A	-875.35%	-37.46%

55.4% of Oncocyte shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Oncocyte currently has a consensus target price of $10.50, indicating a potential upside of 211.57%. Given Oncocyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncocyte is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TransCode Therapeutics has lower revenue, but higher earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	27.23	-$50.22M	-$1.49	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

In the previous week, Oncocyte and Oncocyte both had 2 articles in the media. TransCode Therapeutics' average media sentiment score of 0.44 beat Oncocyte's score of -0.63 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oncocyte beats TransCode Therapeutics on 9 of the 14 factors compared between the two stocks.

How does TransCode Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Black Diamond Therapeutics has a beta of 3.32, suggesting that its stock price is 232% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 4 more articles in the media than TransCode Therapeutics. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 2 mentions for TransCode Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.92 beat TransCode Therapeutics' score of 0.44 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.5% of Black Diamond Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Black Diamond Therapeutics' return on equity of -32.10% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
TransCode Therapeutics	N/A	-875.35%	-37.46%

Black Diamond Therapeutics has higher revenue and earnings than TransCode Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

Black Diamond Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Black Diamond Therapeutics beats TransCode Therapeutics on 13 of the 14 factors compared between the two stocks.

How does TransCode Therapeutics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

OnKure Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

OnKure Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 626.14%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe OnKure Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OnKure Therapeutics' return on equity of -49.01% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
TransCode Therapeutics	N/A	-875.35%	-37.46%

OnKure Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

91.0% of OnKure Therapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, TransCode Therapeutics had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for OnKure Therapeutics. TransCode Therapeutics' average media sentiment score of 0.44 beat OnKure Therapeutics' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
OnKure Therapeutics	Neutral
TransCode Therapeutics	Neutral

Summary

OnKure Therapeutics beats TransCode Therapeutics on 7 of the 13 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAZ vs. The Competition

Export

Metric	TransCode Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.95M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-0.04	13.62	275.30	26.16
Price / Sales	N/A	1,234.33	635.97	107.53
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.17	17.17	11.22	6.33
Net Income	-$34.66M	-$22.69M	$3.50B	$382.15M
7 Day Performance	18.47%	-1.34%	-0.89%	-1.40%
1 Month Performance	10.06%	-8.45%	-4.42%	-3.47%
1 Year Performance	-86.86%	14.02%	7.03%	1.18%

TransCode Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAZ TransCode Therapeutics	1.1399 of 5 stars	$1.86 +8.8%	N/A	-87.4%	$28.95M	N/A	N/A	12	Gap Up
GNLX Genelux	2.3976 of 5 stars	$2.51 +2.2%	$18.00 +618.6%	-54.9%	$113.15M	$10K	N/A	26
RANI Rani Therapeutics	3.1862 of 5 stars	$0.81 +1.3%	$8.75 +978.9%	+67.4%	$112.91M	$1.63M	N/A	69	Analyst Forecast
IMDX Oncocyte	2.2074 of 5 stars	$3.33 -1.6%	$10.50 +215.7%	N/A	$109.30M	$1.67M	N/A	58
BDTX Black Diamond Therapeutics	3.696 of 5 stars	$1.89 +0.8%	$10.25 +443.8%	-57.6%	$108.30M	N/A	N/A	21	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. GNLX, RANI, IMDX, BDTX, and OKUR

How does TransCode Therapeutics compare to Genelux?

Summary

How does TransCode Therapeutics compare to Rani Therapeutics?

Summary

How does TransCode Therapeutics compare to Oncocyte?

Summary

How does TransCode Therapeutics compare to Black Diamond Therapeutics?

Summary

How does TransCode Therapeutics compare to OnKure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. GNLX, RANI, IMDX, BDTX, and OKUR

How does TransCode Therapeutics compare to Genelux?

Does the media favor RNAZ or GNLX?

Which has more risk & volatility, RNAZ or GNLX?

Do insiders & institutionals hold more shares of RNAZ or GNLX?

Which has stronger earnings and valuation, RNAZ or GNLX?

Do analysts prefer RNAZ or GNLX?

Is RNAZ or GNLX more profitable?

Summary

How does TransCode Therapeutics compare to Rani Therapeutics?

Is RANI or RNAZ more profitable?

Which has preferable earnings and valuation, RANI or RNAZ?

Do insiders and institutionals hold more shares of RANI or RNAZ?

Does the media refer more to RANI or RNAZ?

Do analysts prefer RANI or RNAZ?

Which has more risk and volatility, RANI or RNAZ?

Summary

How does TransCode Therapeutics compare to Oncocyte?

Is IMDX or RNAZ more profitable?

Do institutionals and insiders hold more shares of IMDX or RNAZ?

Which has more risk & volatility, IMDX or RNAZ?

Do analysts prefer IMDX or RNAZ?

Which has preferable valuation & earnings, IMDX or RNAZ?

Does the media favor IMDX or RNAZ?

Summary

How does TransCode Therapeutics compare to Black Diamond Therapeutics?

Which has more volatility and risk, BDTX or RNAZ?

Does the media refer more to BDTX or RNAZ?

Do insiders & institutionals hold more shares of BDTX or RNAZ?

Is BDTX or RNAZ more profitable?

Which has higher valuation and earnings, BDTX or RNAZ?

Do analysts rate BDTX or RNAZ?

Summary

How does TransCode Therapeutics compare to OnKure Therapeutics?

Which has more risk and volatility, OKUR or RNAZ?

Do analysts prefer OKUR or RNAZ?

Is OKUR or RNAZ more profitable?

Which has higher valuation & earnings, OKUR or RNAZ?

Do insiders and institutionals hold more shares of OKUR or RNAZ?

Does the media refer more to OKUR or RNAZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools